David Wilkes

Mr. David Wilkes

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ADAditya S. Deshpande
Aditya S. Deshpande
NUNetha Ulahannan
Netha Ulahannan
MPMatthew Pendleton
Matthew Pendleton
XDXiaoguang Dai
Xiaoguang Dai
LLLynn Ly
Lynn Ly
MIMarcin Imieliński
Marcin Imieliński

3 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJoanna Cyrta
Joanna Cyrta
AAAnke Augspach
Anke Augspach
MFMaria Rosaria De Filippo
Maria Rosaria De Filippo
DPDavide Prandi
Davide Prandi
PTPhillip Thienger
Phillip Thienger
MRMark A. Rubin
Mark A. Rubin
Advanced prostate cancer initially responds to hormonal treatment, but ultimately becomes resistant and requires more potent therapies. One mechanism of resistance observed in around 10–20% of these patients is lineage plasticity, which manifests in a partial or complete small cell or neuroendocrine prostate cancer (NEPC) phenotype. Here, we investigate the role of the mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complex in NEPC. Using large patient datasets, patient-derived organoids and cancer cell lines, we identify mSWI/SNF subunits that are deregulated in NEPC and demonstrate that SMARCA4 (BRG1) overexpression is associated with aggressive disease. We also show that SWI/SNF complexes interact with different lineage-specific factors in NEPC compared to prostate adenocarcinoma. These data point to a role for mSWI/SNF complexes in therapy-related lineage plasticity, which may also be relevant for other solid tumors.

19 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
AAAurélie Auguste
Aurélie Auguste
FBFelix BLANC
Felix BLANC
MDMarc DELOGER
Marc DELOGER
AFAudrey Le Formal
Audrey Le Formal
RBRohan Bareja
Rohan Bareja
ALAlexandra Leary
Alexandra Leary
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an aggressive malignancy that occurs in young women, is characterized by recurrent loss-of-function mutations in the SMARCA4 gene, and for which effective treatments options are lacking. The aim of this study was to broaden the knowledge on this rare malignancy by reporting a comprehensive molecular analysis of an independent cohort of SCCOHT cases. We conducted Whole Exome Sequencing in six SCCOHT, and RNA-sequencing and array comparative genomic hybridization in eight SCCOHT. Additional immunohistochemical, Sanger sequencing and functional data are also provided. SCCOHTs showed remarkable genomic stability, with diploid profiles and low mutation load (mean, 5.43 mutations/Mb), including in the three chemotherapy-exposed tumors. All but one SCCOHT cases exhibited 19p13.2-3 copy-neutral LOH. SMARCA4 deleterious mutations were recurrent and accompanied by loss of expression of the SMARCA2 paralog. Variants in a few other genes located in 19p13.2-3 (e.g., PLK5) were detected. Putative therapeutic targets, including MAGEA4, AURKB and CLDN6, were found to be overexpressed in SCCOHT by RNA-seq as compared to benign ovarian tissue. Lastly, we provide additional evidence for sensitivity of SCCOHT to HDAC, DNMT and EZH2 inhibitors. Despite their aggressive clinical course, SCCOHT show remarkable inter-tumor homogeneity and display genomic stability, low mutation burden and few somatic copy number alterations. These findings and preliminary functional data support further exploration of epigenetic therapies in this lethal disease.

3 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AVAram Vosoughi
Aram Vosoughi
TZTuo Zhang
Tuo Zhang
KSKyrillus S. Shohdy
Kyrillus S. Shohdy
PVPanagiotis J. Vlachostergios
Panagiotis J. Vlachostergios
DWDavid Wilkes
David Wilkes
BFBishoy M. Faltas
Bishoy M. Faltas
The prevalence and biological consequences of deleterious germline variants in urothelial cancer (UC) are not fully characterized. We performed whole-exome sequencing (WES) of germline DNA and 157 primary and metastatic tumors from 80 UC patients. We developed a computational framework for identifying putative deleterious germline variants (pDGVs) from WES data. Here, we show that UC patients harbor a high prevalence of pDGVs that truncate tumor suppressor proteins. Deepening somatic loss of heterozygosity in serial tumor samples is observed, suggesting a critical role for these pDGVs in tumor progression. Significant intra-patient heterogeneity in germline-somatic variant interactions results in divergent biological pathway alterations between primary and metastatic tumors. Our results characterize the spectrum of germline variants in UC and highlight their roles in shaping the natural history of the disease. These findings could have broad clinical implications for cancer patients.

7 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
NUNetha Ulahannan
Netha Ulahannan
MPMatthew Pendleton
Matthew Pendleton
ADAditya S Deshpande
Aditya S Deshpande
SSStefan Schwenk
Stefan Schwenk
JBJulie M. Behr
Julie M. Behr
MIMarcin Imielinski
Marcin Imielinski
Higher-order chromatin structure arises from the combinatorial physical interactions of many genomic loci. To investigate this aspect of genome architecture we developed Pore-C, which couples chromatin conformation capture with Oxford Nanopore Technologies (ONT) long reads to directly sequence multi-way chromatin contacts without amplification. In GM12878, we demonstrate that the pairwise interaction patterns implicit in Pore-C multi-way contacts are consistent with gold standard Hi-C pairwise contact maps at the compartment, TAD, and loop scales. In addition, Pore-C also detects higher-order chromatin structure at 18.5-fold higher efficiency and greater fidelity than SPRITE, a previously published higher-order chromatin profiling technology. We demonstrate Pore-C’s ability to detect and visualize multi-locus hubs associated with histone locus bodies and active / inactive nuclear compartments in GM12878. In the breast cancer cell line HCC1954, Pore-C contacts enable the reconstruction of complex and aneuploid rearranged alleles spanning multiple megabases and chromosomes. Finally, we apply Pore-C to generate a chromosome scale de novo assembly of the HG002 genome. Our results establish Pore-C as the most simple and scalable assay for the genome-wide assessment of combinatorial chromatin interactions, with additional applications for cancer rearrangement reconstruction and de novo genome assembly.

26 May 2021 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
MSMayumi Sugita
Mayumi Sugita
DWDavid Wilkes
David Wilkes
RBRohan Bareja
Rohan Bareja
KEKenneth W. Eng
Kenneth W. Eng
SNSarah Nataraj
Sarah Nataraj
MGMonica L. Guzman
Monica L. Guzman
The epichaperome is a new cancer target composed of hyperconnected networks of chaperome members that facilitate cell survival. Cancers with an altered chaperone configuration may be susceptible to epichaperome inhibitors. We developed a flow cytometry-based assay for evaluation and monitoring of epichaperome abundance at the single cell level, with the goal of prospectively identifying patients likely to respond to epichaperome inhibitors, to measure target engagement, and dependency during treatment. As proof of principle, we describe a patient with an unclassified myeloproliferative neoplasm harboring a novel PML-SYK fusion, who progressed to acute myeloid leukemia despite chemotherapy and allogeneic stem cell transplant. The leukemia was identified as having high epichaperome abundance. We obtained compassionate access to an investigational epichaperome inhibitor, PU-H71. After 16 doses, the patient achieved durable complete remission. These encouraging results suggest that further investigation of epichaperome inhibitors in patients with abundant baseline epichaperome levels is warranted.